secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001787306-23-000079
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Biotherapeutics signs license deal with Huadong for ZORYVE in Asia, receiving $30M upfront
--------------------------------------------------------------------------------

- Arcutis grants exclusive license to Huadong for ZORYVE cream and ARQ-154 foam in Greater China and Southeast Asia.
- Huadong pays $30 million upfront, with potential $24 million in development/regulatory milestones and $40.25 million in sales milestones.
- Arcutis receives low double-digit to high-teen double-digit royalties on net sales during the royalty term.
- Huadong is responsible for development, regulatory approval, and commercialization at its own expense.
- The agreement covers dermatological indications and includes termination provisions for breach, insolvency, or IP challenges.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000079/0001787306-23-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000079/arqt-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer